<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762992</url>
  </required_header>
  <id_info>
    <org_study_id>CHULC.CI.452.2018</org_study_id>
    <nct_id>NCT04762992</nct_id>
  </id_info>
  <brief_title>LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)</brief_title>
  <acronym>HepaGrowth</acronym>
  <official_title>Low Molecular Weight Heparin for the Treatment of Early Fetal Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar de Lisboa Central</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NOVA CRU, NOVA Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Hospitalar de Lisboa Central</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal&#xD;
      morbimortality (Miller et al. 2008, Nardozza et al. 2017). Placental thrombosis, infarcts and&#xD;
      hypercoagulability are frequently seen in these pregnancies, suggesting a role for the&#xD;
      activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for&#xD;
      low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational&#xD;
      age at delivery, gestational and fetal morbidity) will be compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FGR is the second leading cause of perinatal mortality, being associated with approximately&#xD;
      30% of stillbirths (Nardozza et al. 2017). Early FGR is associated with substantial&#xD;
      disturbances of placental implantation and fetal hypoxia, which requires fetal cardiovascular&#xD;
      adaptation. Both maternal and fetal Doppler alterations are present, allowing for risk&#xD;
      stratification and monitoring (Arbeille et al. 1995, Nardozza et al. 2017a). Although the&#xD;
      precise etiology for FGR due to placental causes is unknown, placental thrombosis, infarcts&#xD;
      and hypercoagulability are frequently seen, suggesting a role for the activation of the&#xD;
      coagulation cascade in the genesis of FGR (Elder et al. 1976, Bellart et al. 1998, Fuke at&#xD;
      al. 1994). Currently, the management of early FGR is limited to the monitoring of fetal&#xD;
      Doppler parameters until the risks for preterm delivery outweight the benefits of ongoing&#xD;
      monitoring (Seravalli et al. 2015). As such, there is a special need for effective preventive&#xD;
      and therapeutic interventions that improve the outcomes. Low molecular weight heparin (LMWH),&#xD;
      for its anticoagulant and anti-inflammatory properties has been suggested as a possible&#xD;
      therapeutic agent in this setting (Tyrell et al. 1995, Yu et al. 2004, Yu et al. 2010). We&#xD;
      will randomize the participants to two intervention arms in a one-to-one ratio, using a&#xD;
      computer generated randomization program. The randomization will be stratified for&#xD;
      gestational age at diagnosis of FGR (22 to 26 weeks and &gt;26 to 32 weeks). The experimental&#xD;
      group will be administered enoxaparin subcutaneous injections (40 mg, 4000 IU daily) and the&#xD;
      control group will be provided standard of care. Both groups will start intervention&#xD;
      immediately after the diagnosis of FGR, and will continue it until 36 weeks of gestation or&#xD;
      12 hours before delivery, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>pharmacological intervention and standard of care arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Both the pharmacological intervention and the standard of care group will be identified by randomized code ID.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>day of delivery</time_frame>
    <description>Best assessment of the time of gestation, either by first trimester sonography, last menstrual day or day of implantation of in vitro conception product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>live-birth</measure>
    <time_frame>day of delivery</time_frame>
    <description>a live birth occurs when a fetus, whatever its gestational age, is delivered and subsequently shows any sign of life</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <condition>Prematurity</condition>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Intervention group, enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin subcutaneous injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline subcutaneous injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous Enoxaparin</intervention_name>
    <description>Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.</description>
    <arm_group_label>Intervention group, enoxaparin</arm_group_label>
    <other_name>experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>Obsteric standard of care.</description>
    <arm_group_label>Placebo, normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  viable singleton pregnancy&#xD;
&#xD;
          -  early FGR diagnosed according to the 2016 consensus criteria&#xD;
&#xD;
          -  early FGR confirmed by the research centre&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosed fetal chromosomal abnormalities;&#xD;
&#xD;
          -  associated fetal morphological malformations;&#xD;
&#xD;
          -  evidence of fetal infection (serological or after invasive testing);&#xD;
&#xD;
          -  use of aspirin, LMWH or non-fractionated heparin (NFH) in the index pregnancy before&#xD;
             randomization;&#xD;
&#xD;
          -  known allergy to LMWH or NFH;&#xD;
&#xD;
          -  hypersensitivity to porcine products;&#xD;
&#xD;
          -  antecedents of heparin-induced thrombocytopenia;&#xD;
&#xD;
          -  maternal thrombocytopenia (platelets &lt; 100 000);&#xD;
&#xD;
          -  antecedents of anticoagulant hemostatic disorder;&#xD;
&#xD;
          -  diagnosed placental hematoma;&#xD;
&#xD;
          -  diagnosed maternal diabetic retinopathy;&#xD;
&#xD;
          -  bacterial endocarditis;&#xD;
&#xD;
          -  high risk of bleeding (recent ophthalmological, spinal or brain surgery);&#xD;
&#xD;
          -  previous hemorrhagic stroke;&#xD;
&#xD;
          -  persistent high blood pressure (&gt; 160/100 mmHg), despite optimal anti-hypertensive&#xD;
             regimen;&#xD;
&#xD;
          -  active ulcerative or angiodysplastic diseases;&#xD;
&#xD;
          -  severe renal disease (eGFR &lt;30mL/min)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>biologic (genotipic and fenotipic) female sex</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fátima Serrano, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Hospitalar Universitário de Lisboa Central</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catarina Palma-dos-Reis, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar Universitário de Lisboa Central</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catarina Palma-dos-Reis, MD, MSc</last_name>
    <phone>+351 965591030</phone>
    <email>catarina.reis@chlc.min-saude.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana-Teresa Martins, MD</last_name>
    <phone>+351 969 828 232</phone>
    <email>ana.t.martins@chlc.min-saude.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Diagnóstico Pré-Natal, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-170</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Catarina Palma-dos-Reis, MD, MSc</last_name>
      <phone>+351 965591030</phone>
      <email>catarina.reis@chlc.minsaude.pt</email>
    </contact>
    <contact_backup>
      <last_name>Fátima Serrano, MD, PhD</last_name>
      <phone>+351 919 538 642</phone>
      <email>maria.serrano@chlc.min-saude.pt</email>
    </contact_backup>
    <investigator>
      <last_name>Ana-Teresa Martins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Miller J, Turan S, Baschat AA. Fetal growth restriction. Semin Perinatol. 2008 Aug;32(4):274-80. doi: 10.1053/j.semperi.2008.04.010. Review.</citation>
    <PMID>18652928</PMID>
  </reference>
  <reference>
    <citation>Nardozza LMM, Zamarian ACP, Araujo Júnior E. New Definition of Fetal Growth Restriction: Consensus Regarding a Major Obstetric Complication. Rev Bras Ginecol Obstet. 2017 Jul;39(7):315-316. doi: 10.1055/s-0037-1603741. Epub 2017 Jun 12.</citation>
    <PMID>28605820</PMID>
  </reference>
  <reference>
    <citation>Arbeille P, Maulik D, Fignon A, Stale H, Berson M, Bodard S, Locatelli A. Assessment of the fetal PO2 changes by cerebral and umbilical Doppler on lamb fetuses during acute hypoxia. Ultrasound Med Biol. 1995;21(7):861-70.</citation>
    <PMID>7491742</PMID>
  </reference>
  <reference>
    <citation>Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marçal VM, Lobo TF, Peixoto AB, Araujo Júnior E. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017 May;295(5):1061-1077. doi: 10.1007/s00404-017-4341-9. Epub 2017 Mar 11. Review.</citation>
    <PMID>28285426</PMID>
  </reference>
  <reference>
    <citation>Elder MG, Myatt L. Coagulation and fibrinolysis in pregnancies complicated by fetal growth retardation. Br J Obstet Gynaecol. 1976 May;83(5):355-60.</citation>
    <PMID>1268144</PMID>
  </reference>
  <reference>
    <citation>Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles RM, Cabero L. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation. Am J Perinatol. 1998 Feb;15(2):81-5.</citation>
    <PMID>9514130</PMID>
  </reference>
  <reference>
    <citation>Fuke Y, Aono T, Imai S, Suehara N, Fujita T, Nakayama M. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecol Obstet Invest. 1994;38(1):5-9.</citation>
    <PMID>7959327</PMID>
  </reference>
  <reference>
    <citation>Seravalli V, Baschat AA. A uniform management approach to optimize outcome in fetal growth restriction. Obstet Gynecol Clin North Am. 2015 Jun;42(2):275-88. doi: 10.1016/j.ogc.2015.01.005. Review.</citation>
    <PMID>26002166</PMID>
  </reference>
  <reference>
    <citation>Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci. 1995 Jun;16(6):198-204. Review.</citation>
    <PMID>7652929</PMID>
  </reference>
  <reference>
    <citation>Lewander R, Lunell NO, Nylund L, Sarby B, Thornström S. [Uterine-placental blood flow. Method of measurement and clinical use]. Lakartidningen. 1980 Jan 30;77(5):333-4. Swedish.</citation>
    <PMID>7366291</PMID>
  </reference>
  <reference>
    <citation>Seravalli V, Block-Abraham DM, Turan OM, Doyle LE, Blitzer MG, Baschat AA. Second-trimester prediction of delivery of a small-for-gestational-age neonate: integrating sequential Doppler information, fetal biometry, and maternal characteristics. Prenat Diagn. 2014 Nov;34(11):1037-43. doi: 10.1002/pd.4418. Epub 2014 Jun 11.</citation>
    <PMID>24864018</PMID>
  </reference>
  <reference>
    <citation>Picklesimer AH, Oepkes D, Moise KJ Jr, Kush ML, Weiner CP, Harman CR, Baschat AA. Determinants of the middle cerebral artery peak systolic velocity in the human fetus. Am J Obstet Gynecol. 2007 Nov;197(5):526.e1-4.</citation>
    <PMID>17980196</PMID>
  </reference>
  <results_reference>
    <citation>Yu YH, Shen LY, Zou H, Wang ZJ, Gong SP. Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med. 2010 Sep;23(9):980-7. doi: 10.3109/14767050903443459.</citation>
    <PMID>19951008</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu YH, Shen LY, Zhong M, Zhang Y, Su GD, Gao YF, Quan S, Zeng L. [Effect of heparin on fetal growth restriction]. Zhonghua Fu Chan Ke Za Zhi. 2004 Dec;39(12):793-6. Chinese.</citation>
    <PMID>15733401</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fetal Growth Retardation</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Pre-Eclampsia</keyword>
  <keyword>Placenta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

